Derik De Bruin
Stock Analyst at B of A Securities
(4.61)
# 231
Out of 5,041 analysts
220
Total ratings
67.57%
Success rate
15.55%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,437.86 | -3.33% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $224.00 | -1.79% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $42.01 | -35.73% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $99.32 | +10.75% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $39.78 | +25.69% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $13.81 | -5.87% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $49.25 | +7.61% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $358.36 | +4.64% | 14 | Jun 26, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $156 → $128 | $148.70 | -13.92% | 33 | Apr 14, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $7.97 | +38.02% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $64.81 | +0.29% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $10.63 | +50.52% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $574.64 | +14.85% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $221.57 | +6.06% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $198.55 | +5.77% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $304.45 | +16.60% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $27.50 | -5.45% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $284.19 | -4.64% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $183.50 | -0.82% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $11.39 | +84.37% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $22.56 | +41.84% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $101.50 | -1.48% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $73.94 | +16.31% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $4.09 | +217.61% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.24 | +190.83% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $176.23 | +47.53% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $13.53 | +786.92% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $146.59 | -18.14% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $3.16 | +184.81% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $646.81 | -63.67% | 3 | Nov 2, 2018 |
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,437.86
Upside: -3.33%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $224.00
Upside: -1.79%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $42.01
Upside: -35.73%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $99.32
Upside: +10.75%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $39.78
Upside: +25.69%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $13.81
Upside: -5.87%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $49.25
Upside: +7.61%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $358.36
Upside: +4.64%
Agilent Technologies
Apr 14, 2025
Maintains: Neutral
Price Target: $156 → $128
Current: $148.70
Upside: -13.92%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $7.97
Upside: +38.02%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $64.81
Upside: +0.29%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $10.63
Upside: +50.52%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $574.64
Upside: +14.85%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $221.57
Upside: +6.06%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $198.55
Upside: +5.77%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $304.45
Upside: +16.60%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $27.50
Upside: -5.45%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $284.19
Upside: -4.64%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $183.50
Upside: -0.82%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $11.39
Upside: +84.37%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $22.56
Upside: +41.84%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $101.50
Upside: -1.48%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $73.94
Upside: +16.31%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $4.09
Upside: +217.61%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.24
Upside: +190.83%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $176.23
Upside: +47.53%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $13.53
Upside: +786.92%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $146.59
Upside: -18.14%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $3.16
Upside: +184.81%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $646.81
Upside: -63.67%